Invest in Sen-Jam Pharmaceutical

Management’s Discussion and Analysis of Financial Condition and Results of Operations

You should read the following discussion and analysis of our financial condition and results of operations together with our financial statements and the related notes and other financial information included elsewhere in this offering. Some of the information contained in this discussion and analysis, including information regarding the strategy and plans for our business, includes forward-looking statements that involve risks and uncertainties. You should review the "Risk Factors" section for a discussion of important factors that could cause actual results to differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis.

Overview

Impacting billions by fighting inflammation at the source.

We are on a mission to revolutionize not just the way we treat pain, but the way the business of pain relief treats humanity. We love the idea: Pharma for the People. Our products treat at the source; preventing symptoms vs. masking them as most therapies do today. And our products are safe & highly affordable. And that's just good for all of us.

We create new drugs to disrupt pain + inflammation that are highly safe and effective while being remarkably accessible and affordable.

Our goal in the next 5 years is to license or sell all of our assets creating $1,000,000,000 in value for our shareholders.

Milestones

Sen-Jam Pharmaceutical Inc was incorporated in the State of Delaware in August 2017.

Since then, we have:

• INVEST NOW: Sprint to $3M Fractional Royalty Right special limited incentive https://bit.ly/4cKpnPY
• $730M+ in exits by leadership team from MIT, Harvard, Mayo Clinic & Memorial Sloan Kettering
• Over 60 global patents granted and pending
• Portfolio of 11 assets, 4 of which are at or near pivotal Phase 2 clinical trials
• Partnerships with National Institute of Drug Abuse, People Science & Duke University
• Biggest advance tackling inflammation since aspirin was invented 125 years ago
• Backed by corporate venture partner KVK-Tech

The Company is subject to risks and uncertainties common to early-stage companies. Given the Company’s limited operating history, the Company cannot reliably estimate how much revenue it will receive in the future.

Historical Results of Operations

• Revenues & Gross Margin. For the period ended December 31, 2023, and the year ended December 31, 2022, the Company had revenues of $0. Our gross margin was 0% in fiscal years 2023 and 2022.
• Assets. As of December 31, 2023, the Company had total assets of $950,081, including $331,764 in cash. As of December 31, 2022, the Company had $663,018 in total assets, including $181,148 in cash.
• Net Loss. The Company has had net losses of $4,355,706 and net losses of $3,983,709 for the fiscal years ended December 31, 2023 and December 31, 2022, respectively.
• Liabilities. The Company's liabilities totaled $2,867,626 for the fiscal year ended December 31, 2023 and $2,162,993 for the fiscal year ended December 31, 2022.

Related Party Transaction

Refer to Question 26 of this Form C for disclosure of all related party transactions.

Liquidity & Capital Resources

To-date, the company has been financed with $309,476 in equity and $2,471,992 in convertibles.

After the conclusion of this Offering, should we hit our minimum funding target, our projected runway is 3 months before we need to raise further capital.

We plan to use the proceeds as set forth in this Form C under "Use of Funds". We don’t have any other sources of capital in the immediate future.

We will likely require additional financing in excess of the proceeds from the Offering in order to perform operations over the lifetime of the Company. We plan to raise capital in 6 months. Except as otherwise described in this Form C, we do not have additional sources of capital other than the proceeds from the offering. Because of the complexities and uncertainties in establishing a new business strategy, it is not possible to adequately project whether the proceeds of this offering will be sufficient to enable us to implement our strategy. This complexity and uncertainty will be increased if less than the maximum amount of securities offered in this offering is sold. The Company intends to raise additional capital in the future from investors. Although capital may be available for early-stage companies, there is no guarantee that the Company will receive any investments from investors.

Runway & Short/Mid Term Expenses

Sen-Jam Pharmaceutical Inc cash in hand is $205,778.74, as of April 2024. Over the last three months, revenues have averaged $0/month, cost of goods sold has averaged $0/month, and operational expenses have averaged $80,000/month, for an average burn rate of $80,000 per month. Our intent is to be profitable in 36 months.There have been no material changes or trends in finance or operations since our 2023 financials.

Over the next 3-6 months we don't expect any revenue and our expenses are budgeted to be $500k.  We believe $7.5mm is required over the next 18 months to become revenue generating. 

We believe we need $10mm over the next 18 months to start generating revenue.  Profitability will be dependent on the speed at which we can advance our therapeutics and which therapeutics we decide to advance.  Profitability could be achieved sooner if we pull back on our therapeutic development.  This could be good short term but it would have a long term negative effect on profitability and value creation.

We have access to a credit line provided by the Founder/Officer & Director of the company.  

We are in discussion with institutional investors offering a Reg D 506C Convertible Note, and offering a Reg CF Convertible Note. 

All projections in the above narrative are forward-looking and not guaranteed.